10-Q: Kenvue Inc. Reports First Quarter 2024 Results, Net Sales Up Slightly

Kenvue Inc. reported a slight increase in net sales for the first quarter of 2024, alongside a decrease in net income compared to the same period last year.

Summary

• Kenvue Inc.'s net sales for the first quarter of 2024 were $3.894 billion, a 1.1% increase compared to $3.852 billion in the same period of 2023.
• Organic growth, excluding currency impacts, was 1.9%, driven by value realization, partially offset by volume declines.
• Gross profit margin increased to 57.6% from 55.2% year-over-year, due to supply chain optimization and lower material costs.
• Net income decreased to $296 million, or $0.15 per share, compared to $469 million, or $0.27 per share, in the first quarter of 2023.
• The company incurred $41 million in restructuring expenses and a $68 million impairment charge related to its interim headquarters.
• Operating income was $550 million, down from $640 million in the prior year.
• Interest expense increased significantly to $95 million, up from $1 million in the prior year, due to debt financing.
• The worldwide effective income tax rate was 30.7%, up from 23.0% in the prior year.

Sentiment

Score: 4

Explanation: The document presents mixed results with a slight increase in net sales but a significant decrease in net income, along with restructuring costs and an impairment charge. The overall tone is cautious, reflecting the challenges the company is facing.

Positives

• The company experienced a slight increase in net sales.
• Gross profit margin improved due to supply chain optimization and lower material costs.
• Organic growth was positive, driven by value realization.
• The company is actively managing its supply chain and costs.

Negatives

• Net income decreased significantly compared to the same period last year.
• Operating income decreased due to higher expenses.
• The company incurred significant restructuring expenses and an impairment charge.
• Interest expense increased substantially due to debt financing.
• The effective tax rate increased, impacting net income.

Risks

• The company faces increased competition in a highly competitive global marketplace.
• Macroeconomic trends, including global conflicts, may cause economic uncertainty and volatility.
• The company is exposed to foreign currency risk due to its global operations.
• Inflationary pressures may increase the costs of raw materials and other inputs.
• The company is involved in various legal proceedings, including product liability claims.
• The company's ability to collect receivables may be impacted by adverse macroeconomic factors.
• The company is exposed to credit risk from counterparties to financial instrument contracts.

Future Outlook

The company expects to continue incurring separation-related costs through at least fiscal year 2024 and has initiated a multi-year cost optimization initiative expected to result in $550 million in pre-tax restructuring expenses and other charges over the next two years. The company expects to reinvest all or a portion of these benefits in future growth opportunities.

Management Comments

• Management believes that the cost allocations from J&J prior to the Kenvue IPO were a reasonable reflection of the utilization of services provided.
• Management considers that the company's cash balances and funds provided by operating activities, along with borrowing capacity and access to capital markets, provide adequate liquidity to meet all of its current and long-term obligations.
• Management believes that the company's existing cash and cash generated from operations will be sufficient to service its current obligations for at least the next 12 months.

Industry Context

Kenvue operates in the consumer health industry, which is characterized by strong competition, evolving retail landscapes, and changing consumer preferences. The company's performance is influenced by macroeconomic trends, including inflation and global conflicts. The company is focused on leveraging its brand portfolio and digital capabilities to drive growth in this competitive environment.

Comparison to Industry Standards

• Kenvue's gross profit margin of 57.6% is relatively strong compared to some consumer goods companies, but it is important to compare it to direct competitors in the consumer health space.
• The company's operating income margin of approximately 14% is lower than some of its peers, which may indicate higher operating costs or lower pricing power.
• The increase in interest expense is a significant factor impacting net income, which is a common challenge for companies that have recently undergone a spin-off and have taken on debt.
• The company's organic growth of 1.9% is moderate, and it is important to compare this to the growth rates of its direct competitors to assess its relative performance.
• The restructuring and cost optimization initiatives are common strategies for companies seeking to improve profitability and efficiency, and it is important to monitor the impact of these initiatives on Kenvue's future performance.

Legal Proceedings

• The company is involved in numerous product liability claims and lawsuits involving multiple products.
• Claims for personal injury have been made against the company's subsidiary Johnson & Johnson Consumer Inc. (JJCI) related to acetaminophen-containing products.
• The company is involved in litigation related to Zantac sales.
• The company is involved in putative class actions related to benzene contamination of certain sunscreen products.
• The company is involved in putative class actions related to the effectiveness of orally administered phenylephrine (PE).
• The company is involved in putative class actions related to benzoyl peroxide (BPO) OTC acne products.
• The company is a defendant in a cost recovery action related to the clean-up of a section of the Lower Passaic River in New Jersey.
• The company is a party to various proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act.
• The company is responsible for all liabilities on account of or relating to harm arising out of, based upon or resulting from, directly or indirectly, the presence of or exposure to talc or talc-containing products sold outside the United States or Canada.

Related Party Transactions

• The company has entered into various agreements with J&J, including the Separation Agreement, Tax Matters Agreement, Employee Matters Agreement, Intellectual Property Agreement, Trademark Phase-Out License Agreement, Transition Services Agreement, Transition Manufacturing Agreement, and Registration Rights Agreement.
• The company has balances and transactions with J&J and its affiliates, primarily in connection with the Tax Matters Agreement, Transition Services Agreement, and the Transition Manufacturing Agreement.

Stakeholder Impact

• Shareholders may be concerned about the decrease in net income and the increase in expenses.
• Employees may be affected by the restructuring initiatives, including potential workforce reductions.
• Customers may be impacted by changes in product availability or pricing.
• Suppliers may be affected by changes in payment terms or supply chain optimization initiatives.
• Creditors may be impacted by the company's debt obligations and financial performance.

Next Steps

• The company will continue to implement its restructuring and cost optimization initiatives.
• The company will monitor the impact of macroeconomic trends and global conflicts on its business.
• The company will continue to manage its supply chain and costs.
• The company will continue to defend itself in ongoing legal proceedings.
• The company will continue to evaluate the impact of the OECD Pillar Two Framework on its provision for taxes.

Key Dates

Keywords

Kenvue, Consumer Health, Net Sales, Gross Profit, Net Income, Restructuring, Impairment, Organic Growth, Financial Results, Q1 2024